Comprehensive Financial Consultants Institutional Inc. Grows Position in DexCom, Inc. $DXCM

Key Points

• Comprehensive Financial Consultants Institutional Inc. increased its stake in DexCom, Inc. by 67.0% in the second quarter, now owning 21,082 shares valued at approximately $1.84 million.
• Recently, several other hedge funds also boosted their positions in DexCom, indicating significant institutional interest, with 97.75% of the stock owned by hedge funds and institutional investors.
• Analysts have generally positive views on DexCom, with multiple upgrades and a target price increase to $100, reflecting strong expectations for the company’s growth and performance.

Comprehensive Financial Consultants Institutional Inc. raised its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 67.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,082 shares of the medical device company's stock after buying an additional 8,458 shares during the quarter. Comprehensive Financial Consultants Institutional Inc.'s holdings in DexCom were worth $1,840,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DXCM. Nuveen LLC purchased a new stake in shares of DexCom during the first quarter valued at about $554,893,000. Jennison Associates LLC lifted its position in shares of DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after buying an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of DexCom by 171.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after buying an additional 2,015,971 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of DexCom by 2,371.4% during the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock valued at $136,220,000 after buying an additional 1,914,019 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock valued at $691,336,000 after buying an additional 1,868,241 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares in the company, valued at $4,143,868.26. This trade represents a 5.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,849 shares of company stock worth $564,733. Corporate insiders own 0.32% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Piper Sandler increased their price target on shares of DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research report on Thursday, July 31st. William Blair upgraded shares of DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Wall Street Zen downgraded shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Argus assumed coverage on shares of DexCom in a report on Thursday, August 21st. They set a "buy" rating and a $100.00 price objective on the stock. Finally, Raymond James Financial upped their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.32.

DexCom Trading Up 0.9%

DexCom stock opened at $67.05 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The stock's 50 day simple moving average is $76.31 and its two-hundred day simple moving average is $77.93. The firm has a market cap of $26.29 billion, a PE ratio of 46.56, a P/E/G ratio of 1.41 and a beta of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 EPS. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.